Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers Skip to content Home Media Investors Careers Products Licensing Research Responsibility About us Contact us - - Oncology Over 12 million people are diagnosed with cancer each year, and it is predicted to be the leading cause of death in the US by 2005.
ASTRAZENECA MAKES FIRST REGULATORY SUBMISSION FOR USE OF 'CASODEXa„¢' 150MG IN EARLY PROSTATE CANCER Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2001 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
RESULTS FROM LARGEST EVER PROSTATE CANCER STUDY SHOW ASTRAZENECA'S CASODEX ALMOST HALVES RISK OF DISEASE PROGRESSION Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2001 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
FDA ADVISORY COMMITTEE REQUESTS FURTHER DATA ON ASTRAZENECAa€™S CASODEXA® (BICALUTAMIDE) 150 MG FOR EARLY PROSTATE CANCER Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2002 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
AstraZeneca News - press release archive - pharmaceutical news - 2002 Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2002 - - Press release archive 2002 19 December 2002 FDA ADVISORY COMMITTEE...
AstraZeneca Half Year Results 2001-Presentation The future of oral anticoagulation a Page 16 Exanta™ b Ongoing phase III programme: EXPRESS (EU) & EXULT (US) – prevention of VTE SPORTIF – prevention of stroke in AF THRIVE – treatment of VTE b >8,000 patients have received Exanta™ b Initial filings: Prevention of VTE – MAA 3Q 2002/NDA 2Q 2003 Prevention of stroke in AF – MAA/NDA 2Q 2003 a Page 17...
AstraZeneca Second Quarter Results 2001 Presentation The future of oral anticoagulation a Page 16 Exanta™ b Ongoing phase III programme: EXPRESS (EU) & EXULT (US) – prevention of VTE SPORTIF – prevention of stroke in AF THRIVE – treatment of VTE b >8,000 patients have received Exanta™ b Initial filings: Prevention of VTE – MAA 3Q 2002/NDA 2Q 2003 Prevention of stroke in AF – MAA/NDA 2Q 2003 a Page 17...
Database C C - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.Casodex ® (Bicalutamide) (2846) Caspase Inhibitor....
Database B B - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
http://www.adis.com/files/newsletters/CT/Ctcov59.pdf 15 Nov 2003 NoBicalutamide: Casodex 150mg...
http://www.adis.com/files/newsletters/REA/Rxcov976.pdf 20 Granulocyte colony- stimulating factor: fatal splenic 10 Pharmacovigilance & Regulatory News rupture [S] Antidepressants: FDA warns of paediatric suicide risk 2 Hepatitis B vaccine: myasthenia gravis [S] 10 Bicalutamide: Casodex 150mg license withdrawn in UK for 2 Imatinib mesylate: interstitial pneumonia [S] 10 localised prostate cancer Immunosuppressants: fatal drug...
NDAs Approved under Subpart H NDAs Approved under Subpart H NDA # Trade Name Generic -Name Clock Date Approval Date AP Time Approval Basis Indication - - - - - - - - 20199 Hivid Zalcitabine 31-Oct-91 19-Jun-92 7.6 S Combination therapy with zidovudine in advanced HIV infection - - - - - - - - 50698 Biaxin Clarithromycin- 2-Nov-92 23-Dec-93 13.7 S Treatment of disseminated mycobacterial infections due to...
author: Darlene Norris
FDA Drug Approvals List February 2001 Approvable Original New Drug Applications - Original Abbreviated New Drug Applications Original Abbreviated Application # 075402 Approval Date: 28-FEB-01 Trade Name: METAPROTERENOL SULFATE Dosage Form: SOLUTION Applicant: NOVEX PHARMA Active Ingredient(s): METAPROTERENOL SULFATE OTC/RX Status: RX Original Abbreviated Application # 075403 Approval Date: 28-FEB-01 Trade Name:...
Microsoft PowerPoint - Half Year 01 B&W pdf internet version Half Year Results 2001 Dr Tom McKillop Chief Executive Officer a Page 3 Business performance summary b On track to deliver 2001 targets a Page 4 Half Year Results summary Half Year Constant 2001 Currency $m % Sales 8,090 +8 Operating Profit 2,051 +4 EPS $0.87 +7 Continuing (excl
author: m240543
duplicates:http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam11186/Half-Year01-B&W-slides.pdf
Cancer Care Ontario Formulary Information for patients, health professionals and public on cancer prevention, screening, treatment (radiation, chemotherapy, surgery), supportive care, research, education, and standards and guidelines ...
29th European Symposium on Calcified Tissues - Posters 1 to 49 -- Poster Presentations - Abstracts P-1 to P-49 --- Posters will be on display throughout the symposium, but will be attended by their presenting authors as follows: Odd numbers on Monday 12:15 - 14:00 and Wednesday 12:15 - 14:00 Even numbers on Tuesday 12:15 - 14:00 and Wednesday 12:15 - 14:00 Abstracts P49 to P-94 -- --- - Abstracts P-95 to P-140 --- Cancer and bone - P-1 BONE...
27292REVIEWInsF-InsB ASTRAZENECA NOT JUST A PHARMACEUTICAL COMPANY ANNUAL REVIEW 2001 AstraZeneca Annual Review 2001 Key achievements 01 SALES OF $16.5 BILLION, UP 8%* OPERATING PROFIT OF $4.2 BILLION, UP 6%* EARNINGS PER SHARE OF $1.77, UP 11% SHARE BUY- BACK PROGRAMME EXTENDED BY AN ADDITIONAL $2 BILLION PROGRESS WITH RANGE OF PROMISING MEGABRANDS DRIVES TRANSFORMATION STRATEGY NEXIUM ACHIEVES FULL...
author: macuser
duplicates:http://www.astrazeneca.com/annualrep2001/pdf/third.pdf
http://www.cancercare.on.ca/formulary/pdfchemo/leuprolide-bicalu-pc.pdf CODE: LEUPBICALU CCO Formulary Revised November 2001 A REGIMEN NAME LEUPROLIDE- BICALUTAMIDE Therapy Cancer Prostate Cancer (Locally Advanced- Stage C) Prostate Cancer (Metastatic- Stage D) Adjuvant Neoadjuvant Curative Intent Palliative Intent Regimen Category Core: Standard therapy; ...
http://www.cancercare.on.ca/formulary/pdfchemo/goserelin-bicalu-pc.pdf CODE: GOSE– BICALU CCO Formulary Revised November 2001 A REGIMEN NAME GOSERELIN- BICALUTAMIDE Therapy Cancer Prostate Cancer (Locally Advanced- Stage C) Prostate Cancer (Metastatic- Stage D) Adjuvant Intent Neoadjuvant Curative Intent Palliative Intent Regimen Category Core: Standard therapy; ...
A Bicalutamide CCO Formulary Revised July 2001 A DRUG NAME: BICALUTAMIDE COMMON TRADE NAME( S): Casodex® (AstraZeneca) B MECHANISM OF ACTION AND PHARMACOKINETICS Bicalutamide is a selective, non- steroidal anti- androgen similar to flutamide. It binds to the androgen receptors in target tissue ...
author: default
A page 4 Bicalutamide CCO Formulary Revised July 2001 I RECOMMENDED CLINICAL MONITORING Recommended Clinical Monitoring Suggested Clinical Monitoring NO RECOMMENDED TOXICITY RATINGS ° Periodic liver function tests References: Furr BJ. The development of Casodex (bicalutamide): preclinical studies. ...
author: default
A page 1 Bicalutamide CCO Formulary Revised July 2001 A DRUG NAME: BICALUTAMIDE COMMON TRADE NAME( S): Casodex® (AstraZeneca) B MECHANISM OF ACTION AND PHARMACOKINETICS Bicalutamide is a selective, non- steroidal anti- androgen similar to flutamide. It binds to the androgen receptors in target tissue ...
author: default
